Biotechnology

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

With $8M in new funding, Tikva Allocell is advancing a novel cell therapy that uses armored, virus-specific T cells to overcome historical barriers in cancer.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

While debates over UN dues persist, American companies quietly secured over $2 billion in UN contracts, turning global initiatives into a major revenue stream.

Biotech firm ReBio Pharma appoints world-renowned expert Prof. Mandeep Sagoo as CMO, accelerating its novel RBP-01 therapy for uveal melanoma into the clinic.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

A high-level Dubai summit unites tech, pharma, and policy to combat the GCC's escalating IBD crisis, heralding a new era of AI-driven care and IL-23 therapies.

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

San Diego's VivoSim Labs enters China, leveraging AI-powered human tissue models that challenge traditional animal testing and aim for safer, faster drug development.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

SOTIO Biotech's European patent win for its immunocytokine SOT201 wasn't just a legal victory; it's a signpost in the fierce race to redefine cancer care.

A biotech startup is betting it can turn your body into a factory for allergy-fighting cells, aiming to cure diseases, not just treat them. Is this the future?

PolyPid inks a transformative partnership with Azurity for its surgical infection drug, D-PLEX100, securing over $320M and a clear path to market.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.